Dermawan Doni, Alotaiq Nasser
Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Warsaw, 00-661, Poland.
Health Sciences Research Center (HSRC), Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317, Saudi Arabia.
Sci Rep. 2025 Mar 14;15(1):8896. doi: 10.1038/s41598-025-93683-1.
Infection-related cardiovascular diseases (CVDs) pose a significant health challenge, driving the need for novel therapeutic strategies to target key receptors involved in inflammation and infection. Antimicrobial peptides (AMPs) show the potential to disrupt pathogenic processes and offer a promising approach to CVD treatment. This study investigates the binding potential of selected AMPs with critical receptors implicated in CVDs, aiming to explore their therapeutic potential. A comprehensive computational approach was employed to assess AMP interactions with CVD-related receptors, including ACE2, CRP, MMP9, NLRP3, and TLR4. Molecular docking studies identified AMPs with high binding affinities to these targets, notably Tachystatin, Pleurocidin, and Subtilisin A, which showed strong interactions with ACE2, CRP, and MMP9. Following docking, 100 ns molecular dynamics (MD) simulations confirmed the stability of AMP-receptor complexes, and MM/PBSA calculations provided quantitative insights into binding energies, underscoring the potential of these AMPs to modulate receptor activity in infection and inflammation contexts. The study highlights the therapeutic potential of Tachystatin, Pleurocidin, and Subtilisin A in targeting infection-related pathways in CVDs. These AMPs demonstrate promising receptor binding properties and stability in computational models. Future research should focus on in vitro and in vivo studies to confirm their efficacy and safety, paving the way for potential clinical applications in managing infection-related cardiovascular conditions.
感染相关的心血管疾病(CVDs)构成了重大的健康挑战,这促使人们需要新的治疗策略来靶向参与炎症和感染的关键受体。抗菌肽(AMPs)显示出破坏致病过程的潜力,并为心血管疾病的治疗提供了一种有前景的方法。本研究调查了选定抗菌肽与心血管疾病中涉及的关键受体的结合潜力,旨在探索它们的治疗潜力。采用了一种全面的计算方法来评估抗菌肽与心血管疾病相关受体(包括ACE2、CRP、MMP9、NLRP3和TLR4)的相互作用。分子对接研究确定了与这些靶点具有高结合亲和力的抗菌肽,特别是速激肽、杀鲷菌素和枯草杆菌蛋白酶A,它们与ACE2、CRP和MMP9表现出强烈的相互作用。对接后,100纳秒的分子动力学(MD)模拟证实了抗菌肽-受体复合物的稳定性,MM/PBSA计算提供了关于结合能的定量见解,强调了这些抗菌肽在感染和炎症环境中调节受体活性的潜力。该研究突出了速激肽、杀鲷菌素和枯草杆菌蛋白酶A在靶向心血管疾病中感染相关途径方面的治疗潜力。这些抗菌肽在计算模型中表现出有前景的受体结合特性和稳定性。未来研究应集中在体外和体内研究,以确认它们的疗效和安全性,为管理感染相关心血管疾病的潜在临床应用铺平道路。